Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2002

View Archived Issues

Promising early clinical results for dexosome vaccine in melanoma

Clinical data on the proteasome inhibitor PS-341 in multiple myeloma updated

Influence of renal dysfunction on safety profile of pemetrexed

Pharmacokinetics of epothilone B assessed in patients with advanced cancer

Tadalafil reported safe and effective in broad-spectrum erectile dysfunction

No beneficial effects found for nutritional supplementation in fibromyalgia

Preliminary data suggest potential for pramipexole in fibromyalgia

Potential use of pregabalin in fibromyalgia

Novel mu-selective opioid ligand identified at Purdue Pharma

Dyax and Thios enter therapeutic antibody discovery and development collaboration

Chemokine CCR2 and/or CCR3 antagonists under study at Pfizer

Ferring and Johnson & Johnson to develop new generation of type 2 diabetes drugs

NeuroSearch claims modulators of monoamine receptors and transporters with broad applications

Prodrug-based antiinfectives objective of Ricerca and ProQuest collaboration

Novel HIV reverse transcriptase inhibitors in Medivir pipeline

Pharmacia researchers describe new CDK inhibitors for cancer and other indications

Progen receives clearance to begin PI-166 clinical trial

Servier and ConjuChem report novel albumin-binding metalloproteinase inhibitors

Serono and Ivax to develop and commercialize oral cladribine for MS

Novartis to sell Leucomax rights to Schering-Plough

Oryx to market Angiomax in Canada

Replagal E.U. labeling expanded to include treatment of females

Potential for OPC-14523 in bulimia nervosa and OCD

Novel mglu5 receptor antagonists as potential anxiolytic agents

Anxiolytic profile of PNU-57378E evaluated in rodent models

Novartis acquires rights to AGE breaker from Torrent

SuperGen to begin Orathecin NDA submission by year-end 2002

Biovail receives tentative FDA approval for Flash Dose zolpidem

Pravachol approved for use in pediatric patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...